sotorasib continues to show potential in kras-mutant nsclc | ferdinandos skoulidis
Published 3 years ago • 954 plays • Length 3:58Download video MP4
Download video MP3
Similar videos
-
2:59
sotorasib outperforms docetaxel in previously treated kras-mutated nsclc | melissa johnson
-
6:28
codebreak 100: sotorasib in kras-mutated nsclc
-
2:52
kras-mutant nsclc: codebreak 100 trial of sotorasib
-
2:32
codebreak 100: patient-reported outcomes evaluating sotorasib in kras p.g12c mnsclc
-
3:01
phase ii codebreak 100 trial of sotorasib in advanced nsclc
-
1:56:56
dr. skoulidis and terri conneran discuss treatment strategy for lung, colon, and pancreatic cancers
-
1:39
sotorasib shows superior pfs and orr compared to docetaxel for nsclc
-
1:15
gracecastuc-054_lung_wakelee: my approach to repeat biopsies for adv. nsclc with insufficient tissue
-
4:59
case study: treating kras-mutant adenocarcinoma
-
6:09
expert video report on therapeutic advances in nsclc from 2021 asco annual meeting
-
11:11
adjuvant immunotherapy: questions/concerns - leading developments & current questions in lung cancer
-
1:28
dr. forster on recent data with lurbinectedin in sclc
-
54:53
development of a commercial manufacturing process for sotorasib, a first-in-class krasg12c inhibitor
-
3:39
stf recycling switch to sortex® flake sorting solution
-
1:08
taking on the challenge of lung cancer
-
2:07
extensive-stage sclc: potential in the caspian trial
-
1:58
codebreak100: detecting mechanisms of intrinsic resistance by ctdna
-
1:46
challenges and opportunities for patients with advanced nsclc